Zyxel 10G PON IAD Receives BBF.247 Certification from the Broadband Forum
Zyxel Communications announced the company’s flagship WiFi 6 product, the AX7501-B0, has successfully completed the Broadband Forum’s international BBF.247 GPON Certification Program and is XGS-PON certified.
“Broadband Forum’s BBF.247 certification program sets the industry standard when it comes to data and technology interoperability for service providers,” said James Harris, Product Director, EMEA at Zyxel Communications. “This certification accelerates IOP integrations for multi-vendor OLTs that have already deployed, while also giving operators the confidence to complete larger, more complex deployments and still reduce churn.”
Leveraging Zyxel’s OPAL software already deployed to millions of devices, the AX7501 helps service providers deploy and migrate to new technologies fast and easily. In addition to the AX7501’s technical capabilities, Zyxel’s BBF.247 certification is representative of the company’s industry- next-generation fiber access solutions.
The Broadband Forum’s BBF.247 Certification Program has helped pave the way for new broadband technologies by addressing a variety of ONUs; testing various VLAN profiles and functionality. Certification of ONU devices assures conformance with the Broadband Forum’s TR-156 and TR-280 specifications, as well as the International Telecommunication Union’s G.998 GPON standards.
About AX7501
Zyxel AX7501 10G Fiber PON IAD supports 10GbE LAN with reserved SFP+ cage, enabling next-generation 10G active fiber/XGS-PON/ Ethernet functionality. The AX7501 provides low-latency, ultra-high-speed fiber connectivity for an unsurpassed user experience that is powered by the latest in WiFi 6 technology. The AX7501 features fully EasyMesh compliant Zyxel MPro Mesh™ Solutions, providing self-adapting, easy-to-manage whole-home WiFi coverage. TR-069 standard management specifications lower OPEX by allowing service providers to configure, monitor and diagnose client devices remotely.
Availability
AX7501 is currently available for service providers throughout Europe, the Middle East and Africa. Service providers can contact their local Zyxel Communications representatives to learn more about availability or send an e-mail to isp@zyxel.eu. More information about AX7501 can be found here.
About Zyxel Communications
Zyxel Communications delivers technological innovations and has connected the world to the internet for more than 30 years. Whether establishing access through fixed or mobile broadband solutions, Zyxel Communications offers a comprehensive and flexible portfolio of products that’s keeping service providers ahead of the competition.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005699/en/
Contact information
Media contact
Birgitte Dolevert Larsen
Zyxel Communications
birgitte.larsen@zyxel.eu
+45 2085 9223
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology17.9.2025 09:57:00 EEST | Press release
Almirall, S.A. (ALM) a global biopharmaceutical company dedicated to medical dermatology, is a major contributor to the 2025 European Academy of Dermatology and Venereology Congress (EADV) presenting new data across its broad portfolio of dermatological treatments including new real-world data of lebrikizumab on atopic dermatitis, new clinical data of tildrakizumab on psoriasis and tirbanibulin on actinic keratosis. The 34th EADV congress will take place from September 17 to 20 in Paris, France. At the congress, Almirall contributes a total of 44 scientific abstracts focused on advancing patient care across the company’s broad portfolio of dermatological treatments including atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa. With a strong emphasis on real-world evidence, patient-reported outcomes, and well-being, Almirall’s scientific programme includes multiple presentations, two expert-led symposia on psoriasis and atopic dermatitis, and an interactive exh
SES delivered unprecedented MEO satellite connectivity for French Navy’s Clemenceau 25 mission17.9.2025 09:50:00 EEST | Press release
SES announced today that the French Navy’s aircraft carrier Charles de Gaulle leveraged its secure and reliable O3b mPOWER satcom service – Managed Naval mPOWERED – during the Clemenceau 25 mission. This high-throughput, low-latency Medium Earth Orbit (MEO) connectivity solution supported all of the aircraft carrier’s operations, while facilitating collaboration with mission partners. During the five-month deployment, the French Carrier Strike Group (GAN) covered 40,000 nautical miles and conducted various exercises and joint activities with around twenty allied nations. The connectivity provided by SES ensured optimal performance and uninterrupted operational availability for the aircraft carrier’s mission-critical applications. Thanks to the global reach, reliability and exceptional high-speed capacity of the Managed Naval mPOWERED solution, which can deliver several hundred Mb/s of guaranteed throughput, the Charles de Gaulle aircraft carrier enjoyed continuous connectivity througho
Deepfakes Already Hitting Businesses as Often as Traditional Fraud, Regula Survey Finds17.9.2025 09:00:00 EEST | Press release
Fresh survey data from Regula, a global developer of identity verification (IDV) solutions and forensic devices, shows that the line between traditional fraud and impersonation attacks has vanished. Identity spoofing, biometric fraud, and AI-powered deepfakes have already struck one in three organizations worldwide, catching up with long-standing fraud tactics like forged documents and social engineering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916314726/en/ Regula’s survey shows that impersonation attacks overtake traditional fraud schemes. Three impersonation-driven tactics now dominate the fraud playbook, each exploiting weaknesses in verification: Identity spoofing (reported by 34% of organizations) — Holding up a printed photo, replaying a video, or showing a screen image to a camera. Often used to mass-open accounts for scams or mule networks. Biometric fraud (34%) — Physical deceptions like fake fingerprints
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 202517.9.2025 08:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced new 24-week interim data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). These data will support the planned regulatory submissions for povorcitinib in HS in Europe and the United States in 2025 and early 2026, respectively. The presentation will take place today at 2:45 p.m. CEST during a late-breaking oral presentation (Session: Late Breaking News; Presentation ID D1T01.1C) at the European Association of Dermatology and Venereology (EADV) 2025 Congress. “HS remains a challenging and often debilitating condition and many patients are in need of new, well-tolerated and effective therapies that address prominent signs and symptoms of the disease, including inflammatory lesions and pain,” said Pablo J. Cagnoni, M.D., President and Head of Res
Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin17.9.2025 08:00:00 EEST | Press release
Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and their associated environmental factors on individuals with sensitive skin.1 Results from the study, conducted by dermatology experts from Galderma’s Global Sensitive Skincare Faculty (GSSF), will be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress on Friday, September 19. The findings provide compelling evidence that modern, urban lifestyles are associated with worsened skin health in people with sensitive skin.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916245806/en/ Sensitive skin affects up to 70% of people globally – a figure that has risen by 68% over the past two decades – yet it remains widely overlooked and under-studied.2,3 As more people live fast-paced lives in densely populated urban cities, growing evidence
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom